TWD 70.2
(-2.9%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 164.9 Million TWD | 52.41% |
2022 | 108.2 Million TWD | 2.02% |
2021 | 106.06 Million TWD | 9.11% |
2020 | 97.2 Million TWD | 1.3% |
2019 | 95.95 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 133.22 Million TWD | -19.21% |
2024 Q2 | 178.3 Million TWD | 33.84% |
2023 FY | 164.9 Million TWD | 52.41% |
2023 Q4 | 164.9 Million TWD | 17.61% |
2023 Q3 | 140.21 Million TWD | -2.71% |
2023 Q2 | 144.12 Million TWD | 38.95% |
2023 Q1 | 103.72 Million TWD | 0.0% |
2022 Q4 | - TWD | 0.0% |
2022 FY | 108.2 Million TWD | 2.02% |
2021 FY | 106.06 Million TWD | 9.11% |
2020 FY | 97.2 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BIONET Corp. | 626.46 Million TWD | 73.677% |
DIVA Laboratories, Ltd. | 210.93 Million TWD | 21.819% |
Welgene Biotech Co.,Ltd. | 247.89 Million TWD | 33.477% |
Puriblood Medical Co., Ltd. | 84.35 Million TWD | -95.501% |
TFBS Bioscience Inc. | 187.43 Million TWD | 12.02% |